Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11052003 | 0.78 | EPHX1 (0.64) | ALDH1A1EPHX1CYP1A2TSHRSPHK1 | |
| SCHEMBL16841232 | 0.77 | ALDH1A1 (0.61) | ALDH1A1EPHX1CYP1A2 | |
| SCHEMBL14193315 | 0.76 | ALDH1A1 (0.46) | ALDH1A1EPHX1CYP1A2DRD1DNM1 | |
| SCHEMBL9286366 | 0.75 | EPHX1 (0.50) | ALDH1A1EPHX1CYP1A2DNM1 | |
| SCHEMBL7155873 | 0.75 | EPHX1 (0.60) | ALDH1A1EPHX1CYP1A2TSHR | |
| SCHEMBL4446169 | 0.75 | ALDH1A1 (0.46) | ALDH1A1EPHX1CYP1A2DRD1MEN1 | |
| SCHEMBL7155865 | 0.75 | EPHX1 (0.60) | ALDH1A1EPHX1CYP1A2TSHR | |
| SCHEMBL4464256 | 0.75 | EPHX1 (0.60) | ALDH1A1EPHX1CYP1A2TSHR | |
| SCHEMBL6479195 | 0.74 | EPHX1 (0.59) | ALDH1A1EPHX1CYP1A2TSHR | |
| Dodecane SCHEMBL28901762 | 0.73 | ALDH1A1 (0.62) | ALDH1A1EPHX1DNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| EP-2567693-A1 | Lipid encapsulated interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2013-03-13 | — | — | EP | disclosed |
| EP-1664316-B1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS INC (CA) | 2012-08-29 | — | — | EP | disclosed |
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-03-08 | — | — | US | disclosed |
| US-7982027-B2 | silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell; hepatitis | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-07-19 | — | — | US | disclosed |
| US-20110091525-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-04-21 | — | — | US | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-10-26 | — | — | US | disclosed |
| WO-2006074546-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-07-20 | — | — | WO | disclosed |
| EP-1664316-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | Protiva Biotherapeutics Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-08-11 | — | — | US | disclosed |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005026372-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091525-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | LIPA, PNLIP, PLTP | ALDH1A1 2323/4885EPHX1 733/4885CYP1A2 3092/4885 |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | ABHD16A, LDLR, RNASE1 | ALDH1A1 3762/4885EPHX1 3325/4885CYP1A2 4876/4885 |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | LIPA, PNLIP, PLTP | ALDH1A1 2323/4885EPHX1 733/4885CYP1A2 3092/4885 |
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | ALDH1A1 3762/4885EPHX1 3325/4885CYP1A2 4876/4885 |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | ALDH1A1 3762/4885EPHX1 3325/4885CYP1A2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.